Cancer Vaccine

Pic:getty/aydinmutlu

Moderna & Merck plan Phase 3 trial for cancer vaccine with Keytruda

By Rachel Arthur

An mRNA cancer vaccine, in combination with Keytruda, reduced the risk of recurrence or death in melanoma patients by 44% compared to Keytruda alone, according to Phase 2b data. Merck and Moderna plan to initiate a Phase 3 study in the coming months.

Pic:getty/drmicrobe

Building an mRNA giant: Moderna’s 7 priorities for 2023

By Rachel Arthur

mRNA pioneer Moderna wants to grow and thrive past its initial COVID-19 vaccine success. “To continue to build the best version of Moderna, we have established seven priorities for 2023,” says CEO Stephane Bancel: as the company outlines goals that range...

Pic:getty/oatawa

CureVac acquires Frame Cancer Therapeutics

By Rachel Arthur

CureVac has acquired Frame Cancer Therapeutics: with the German mRNA specialist planning to draw on Frame’s expertise in antigen identification and validation as it develops mRNA cancer vaccines.

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All